Navigation Links
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
Date:3/15/2012

HELSINKI, Finland, March 15, 2012 /PRNewswire/ -- CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

The purpose of this study is to demonstrate that Fibrinogen Concentrate (Human)(FCH) can reduce intraoperative bleeding and, therefore, the volume of donor blood products (e.g., fresh frozen plasma, platelets, and red blood cells) needed during complex cardiovascular surgical procedures such as aortic aneurysm surgery. The study will also aim to show that FCH is safe and well tolerated. The primary efficacy endpoint measurement will be the number of units of all allogeneic blood products transfused during the first 24 hours after administration of FCH or placebo. 

"Potentially life-threatening bleeding events can occur during cardiovascular surgery because the patient's fibrinogen levels are depleted, which delays clotting," said Dr. Niels Rahe-Meyer, Department of Anesthesiology and Intensive Care, Franziskus Hospital, Bielefeld, Germany and coordinating investigator  of the study. "The REPLACE Phase III study will help determine if FCH treatment can safely reduce the number of transfusions needed during cardiovascular surgery. If this is the case, we will have a powerful new option for use in protecting cardiovascular surgery patients from potentially life-threatening bleeding and transfusion-associated adverse events and discomfort." 

Of the 12 million units of blood used in the United States each year, 15 percent are used in cardiovascular surgery. Studies have shown that blood transfusion during or after adult cardiac surgery is associated with increased long-term mortality.

"As a global leader in the development of plasma-derived and recombinant coagulation factors for bleeding disorders, we are pleased that this important Phase III study of FCH in aortic aneurysm surgery is underway," said Russell Basser, M.D., Senior Vice President, Global Clinical R&D. "CSL Behring is committed to exploring the use of FCH in patients at high risk of bleeding resulting from cardiac surgery and providing optimal, uncompromised therapy to cardiac surgery teams and patients." 

About the REPLACE Study

REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery) is a Phase III, prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, two-arm study. Patients undergoing elective thoracic aortic surgery are randomized in a 1:1 ratio to treatment with FCH or placebo. Patients will receive a single intra-operative infusion if their blood loss amounts to 60 to 250g in 5 minutes after initial surgery is completed. Following infusion, a second 5-minute bleeding mass measurement is undertaken. If blood loss then still amounts to 60 g or more, the patient will be treated according to a predefined, standardized treatment regimen using allogeneic blood products. Reduction of allogenic blood products and other efficacy endpoints in addition to safety endpoints will be measured according to the trial protocol. For more information visit www.clinicaltrials.gov and search with identifier: NCT01475669.

About Fibrinogen and Fibrinogen Concentrate

Fibrinogen, also called Factor I, is a protein needed to form blood clots and, thereby, to stop bleeding. Fibrinogen levels in plasma determine the potential clotting ability and activity in the body. Diminished concentrations of fibrinogen limit the body's ability to form a clot and increase the risk of uncontrolled bleeding. A simple blood test can detect the level of fibrinogen; the normal range is 2-4 grams per liter. In patients undergoing cardiopulmonary bypass surgery, the plasma concentration of fibrinogen has been reported to decrease by 34 to 42 percent, which can increase the risk of post-operative bleeding. During manufacture, CSL Behring's purified, pasteurized, fibrinogen concentrate undergoes multiple steps to remove potential pathogens, including being heated in aqueous solution at 60 degrees centigrade/140 degrees Fahrenheit for 20 hours. A publication by the World Federation of Hemophilia provides additional perspective on this matter. Fibrinogen concentrate is mostly tolerated without undesirable reactions. In rare cases allergoid-anaphylactoid reactions (like generalized urticaria, rash, fall in blood pressure, dyspnoea), and/or rise in temperature are observed. If allergoid-anaphylactoid reactions occur, the administration of fibrinogen concentrate has to be discontinued immediately (e.g. by interruption of the injection/infusion) and an appropriate treatment has to be initiated. The current medical standards for shock treatment are to be observed. There is a potential risk of thromboembolic episodes (including myocardial infarction and pulmonary embolism) following the administration of human plasma fibrinogen concentrate.

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens. The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV. These measures may possibly be of limited value against non-enveloped viruses such as HAV and parvovirus B19.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited  (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.  
 

Media Contact:
Sheila A. Burke, Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
610-878-4209 (o)
484-919-2618 (c)
Sheila.Burke@cslbehring.com

Etanjalie Ayala
Weber Shandwick
212-445-8225
eayala@webershandwick.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
2. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
3. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
4. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
5. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
6. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
7. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
8. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
9. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
10. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
11. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli Lilly ... William Sansum Diabetes Center have established a research collaboration ... diabetes through enhanced research, education and care. ... bears a disproportionate weight on Latino families in ... Kerr , M.D., FRCPE, director of Innovation and Research ...
(Date:3/23/2017)... Summary Global ... guide Primary Hyperoxaluria - Pipeline Review, H1 2017, ... Urinary System And Sex Hormones) pipeline landscape. ... recurrent kidney and bladder stones. It results from ... include blood in the urine, pain when urinating, ...
(Date:3/23/2017)... March 23, 2017  Digital Pharmacist Inc. ( ... a rapidly growing digital health company, announced today ... that allows patients to manage their prescriptions. Over ... as Denver Health Pharmacy, USave Pharmacy and Owen,s ... Digital Pharmacist accelerate its product development schedule, the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association ... The annual awards, now in their 12th year, are among the most prestigious in ... In 2016, the awards were retooled to recognize achievements in both large budget (over ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, ... treatments for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint ... the obstructive type, is increasingly being treated at dental offices with newly developed ...
(Date:3/24/2017)... ... 24, 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ... for colonoscopy at the HyGIeaCare® Center that is to be located adjacent to ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), ...
Breaking Medicine News(10 mins):